Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3QDA6)

• Drug Name: Polynoma-1 Drug Info
• Synonyms: Polyvalent melanoma vaccine, Vaccinoma

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM3QDA6

Molecule-Related Drug Atlas

Drug(s) Targeting Melanoma-associated antigen 3 (MAGEA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Astuprotimut-R	DMLY0H5	Non-small-cell lung cancer	2C25.Y	Phase 3	[2]
IDM-2101	DMABRXY	Colorectal cancer	2B91.Z	Phase 2	[3]
GL-0817	DM17OZM	Head and neck cancer	2D42	Phase 2	[4]
KITE-718	DMBSI6Y	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[6]

Drug(s) Targeting MART-1 melanoma antigen (MLANA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[7]
Melanoma vaccine	DMQEC6Z	Melanoma	2C30	Phase 3	[8]
MKC-1106-MT	DMXKOW6	Melanoma	2C30	Phase 2	[9]
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[6]
F-50040	DMMG6W5	Melanoma	2C30	Discontinued in Phase 1	[10]

Drug(s) Targeting Tyrosinase (TYR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[11]
Monobenzone	DMVJS2K	Vitiligo	ED63.0	Approved	[11]
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[7]
Melanoma vaccine	DMQEC6Z	Melanoma	2C30	Phase 3	[8]
MKC-1106-MT	DMXKOW6	Melanoma	2C30	Phase 2	[9]
Multi-epitope tyrosinase/gp100 vaccine	DMN68ZL	Melanoma	2C30	Phase 2	[12]
PMID29130358-Compound-Figure11(3)	DMSME2B	N. A.	N. A.	Patented	[13]
Benzothiazole analog 1	DMHXFCQ	Albinism	EC23.2	Patented	[14]
Monoamine derivative 2	DMAZ6DI	Albinism	EC23.2	Patented	[14]
Benzimidazole derivative 3	DMY93WG	Albinism	EC23.2	Patented	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
MART-1 melanoma antigen (MLANA)	TT362RB	MAR1_HUMAN	Not Available	[1]
Melanoma-associated antigen 3 (MAGEA3)	TTWSKHD	MAGA3_HUMAN	Not Available	[1]
Tyrosinase (TYR)	TTULVH8	TYRO_HUMAN	Not Available	[1]

References

• [1] An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
• [2] National Cancer Institute Drug Dictionary (drug id 600553).
• [3] Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health.
• [6] Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.
• [7] Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
• [8] National Cancer Institute Drug Dictionary (drug id 685201).
• [9] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [10] Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8.
• [11] Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
• [12] ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
• [13] Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
• [14] Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.